Comparative effectiveness, safety, and costs of rivaroxaban and warfarin among morbidly obese patients with atrial fibrillation

• Published in: The American heart journal Vol. 212; pp. 113 - 119
• Main Authors: Peterson, Eric D., Ashton, Veronica, Chen, Yen-Wen, Wu, Bingcao, Spyropoulos, Alex C.
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01.06.2019; Elsevier Limited
• Subjects: Anticoagulants; Anticoagulants - economics; Anticoagulants - therapeutic use; Atrial Fibrillation - complications; Atrial Fibrillation - drug therapy; Atrial Fibrillation - epidemiology; Bleeding; Body mass; Body mass index; Body size; Body weight; Cardiac arrhythmia; Codes; Committees; Comorbidity; Confidence intervals; Costs; Diabetes; Diagnostic systems; Drug Costs; Embolism; Embolisms; Factor Xa Inhibitors - economics; Female; Fibrillation; Follow-Up Studies; Health care; Health risks; Heart failure; Heart transplantation; Heart valves; Humans; Hypertension; Identification methods; Incidence; Ischemia; Male; Medicare; Middle Aged; Morbidity - trends; Obesity; Obesity, Morbid - complications; Obesity, Morbid - epidemiology; Patients; Pharmacy; Population; Prescription drugs; Resource utilization; Retrospective Studies; Rivaroxaban - economics; Rivaroxaban - therapeutic use; Statistical analysis; Statistical models; Stenosis; Stroke; Stroke - epidemiology; Stroke - etiology; Stroke - prevention & control; Survival Rate - trends; United States - epidemiology; Warfarin; Warfarin - economics; Warfarin - therapeutic use; United States
• DOI: 10.1016/j.ahj.2019.02.001
• ISSN: 0002-8703; 1097-6744

There are limited data regarding clinical outcomes and healthcare resource utilization of direct oral anticoagulants (DOACs) in patients with atrial fibrillation (AF) who are morbidly obese (body mass index >40 kg/m2 or body weight >120 kg). Using data from 2 US healthcare claims databases, we identified patients initiating rivaroxaban or warfarin who had ≥1 medical claim with an AF diagnosis, a diagnostic code for morbid obesity (ICD-9: 278.01, V85.4%; ICD-10: E66.01%, E66.2%, Z68.4%), and a minimum continuous enrollment of 12 months before and 3 months after treatment initiation. Patients were excluded if they had mitral stenosis, a mechanical heart valve procedure, an organ/tissue transplant, or an oral anticoagulant prescription prior to the index date. Rivaroxaban and warfarin patients were 1:1 propensity score matched. Conditional logistic regression was used to compare ischemic stroke/systemic embolism and major bleeding risk. Generalized linear models were used to compare healthcare resource utilization and costs. A total of 3563 matched pairs of morbidly obese AF patients treated with rivaroxaban or warfarin were identified. The majority (81.4%) of patients in the rivaroxaban cohort were receiving the 20 mg dose. The rivaroxaban and warfarin cohorts were well balanced after propensity score matching. The risks of ischemic stroke/systemic embolism and major bleeding were similar for rivaroxaban and warfarin users (stroke/systemic embolism: 1.5% vs 1.7%; odds ratio [OR]: 0.88; 95% confidence interval [CI]: 0.60, 1.28; P = .5028; major bleeding: 2.2% vs 2.7%; OR: 0.80; 95% CI: 0.59, 1.08; P = .1447). Total healthcare costs including medication costs per patient per year (PPPY) were significantly lower with rivaroxaban versus warfarin ($48,552 vs $52,418; P = .0025), which was primarily driven by lower hospitalization rate (50.2% vs 54.1%; P = .0008), shorter length of stay (7.5 vs 9.1 days; P = .0010), and less outpatient service utilization (86 vs 115 visits PPPY; P < .0001). Morbidly obese AF patients treated with rivaroxaban had comparable risk of ischemic stroke/systemic embolism and major bleeding as those treated with warfarin, but lower healthcare resource utilization and costs.